Pseudoatrophy of the brain with valproic acid monotherapy.
A patient is described who, while on valproic acid monotherapy, developed reversible shrinkage of the brain, documented by computerized tomography with associated cognitive deficit. Although pseudoatrophy has been reported with steroid therapy, this is the first implication of an anticonvulsant drug in the etiology of that condition.
D000293:Adolescent; D001284:Atrophy / Q000139:chemically induced; D001921:Brain / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000473:pathology; D002552:Cerebral Ventricles / Q000473:pathology; D003072:Cognition Disorders / Q000139:chemically induced / Q000503:physiopathology; D004569:Electroencephalography; D004830:Epilepsy, Tonic-Clonic / Q000188:drug therapy; D005260:Female; D005625:Frontal Lobe / Q000503:physiopathology; D006801:Humans; D014057:Tomography, X-Ray Computed; D014635:Valproic Acid / Q000009:adverse effects* / Q000627:therapeutic use
D014635:Valproic Acid